NASDAQ$CDXS
Codexis Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Codexis reported a net loss for Q4 2022, but total revenues increased compared to Q4 2021.
Codexis reported a 24% increase in total revenue for Q4 2022, driven by enzyme sales related to PAXLOVIDTM. However, excluding these sales, total revenues decreased slightly. The company is prioritizing programs in life sciences, biotherapeutics, and pharmaceutical manufacturing.
- Total revenues for Q4 2022 increased by 24% to $30.4 million compared to $24.5 million in Q4 2021.
- Excluding PAXLOVIDTM enzyme sales, total revenues for Q4 2022 decreased by 2% to $13.0 million.
- Net loss for Q4 2022 was $12.6 million, or $0.19 per share, compared to $10.2 million, or $0.16 per share, for Q4 2021.
- Codexis is focusing on life sciences, biotherapeutics, and pharmaceutical manufacturing, with upcoming milestones including IND applications for PKU, EPI, and Fabry disease.
Headline financials
Revenue & EPS history
Codexis · Revenue · Quarterly
$30.4M
Forward guidance
Codexis expects total revenues to be in the range of $63 million to $68 million in 2023, excluding revenue from enzyme sales related to PAXLOVIDTM. The company anticipates that its existing cash and cash equivalents will be sufficient to fund its planned operations through the end of 2024.
Tailwinds
- Total revenues are expected to be in the range of $63 million to $68 million.
- Product revenues are expected to be in the range of $35 million to $40 million, excluding enzyme sales related to PAXLOVIDTM.
- Gross margin on product revenue is expected to be 68% to 73%, excluding enzyme sales related to PAXLOVIDTM.
- Existing cash and cash equivalents will be sufficient to fund planned operations through the end of 2024.
- Focus on high-potential development programs.
Headwinds
- Revenue guidance excludes enzyme sales related to PAXLOVIDTM.
- Dependent on collaborators.
- Biotherapeutic programs are early stage and expensive.
- May need additional capital in the future.
- Market and economic conditions may negatively impact business.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-0.4%
Avg return
Earnings day
-0.0%
Avg return
5 days after
+1.2%
Avg return
30 days after
48%
31 / 64 earnings
Positive
+33.9%
Q4 2025
Best reaction
-24.5%
Q2 2012
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.0% | -4.5% | -4.5% | |
| Q4 2025 | +33.9% | +15.7% | +76.4% | |
| Q3 2025 | -4.3% | -8.9% | -26.7% | |
| Q1 2025 | +1.2% | -0.8% | -9.7% | |
| Q4 2024 | -22.6% | -30.5% | -28.5% | |
| Q3 2024 | +9.0% | +19.0% | +42.7% | |
| Q2 2024 | -7.3% | -7.3% | -9.3% | |
| Q1 2024 | +26.0% | +13.5% | +8.7% | |
| Q4 2023 | +12.0% | +1.4% | -15.9% | |
| Q3 2023 | +16.3% | +4.8% | +48.8% | |
| Q2 2023 | -10.0% | -28.7% | -43.9% | |
| Q1 2023 | -8.1% | -24.4% | -35.7% | |
| Q4 2022 | -14.0% | -12.0% | -29.5% | |
| Q3 2022 | +10.3% | +4.9% | -1.4% | |
| Q2 2022 | +12.5% | +0.0% | -13.4% | |
| Q1 2022 | -9.2% | -17.3% | -20.9% | |
| Q4 2021 | +15.9% | +13.5% | +13.1% | |
| Q3 2021 | +18.8% | +18.7% | -3.7% | |
| Q2 2021 | +17.2% | +18.6% | +29.2% | |
| Q1 2021 | -5.0% | -9.9% | -0.4% | |
| Q4 2020 | -3.4% | -1.3% | -9.6% | |
| Q3 2020 | +2.3% | +9.1% | +23.9% | |
| Q2 2020 | +6.8% | +1.9% | -4.9% | |
| Q1 2020 | +2.3% | -2.9% | +2.2% | |
| Q4 2019 | -10.2% | -12.2% | -20.6% | |
| Q3 2019 | +10.1% | +11.4% | +10.0% | |
| Q2 2019 | -14.4% | -14.9% | -15.9% | |
| Q1 2019 | -5.7% | -3.3% | -11.9% | |
| Q4 2018 | -1.6% | -5.3% | -7.7% | |
| Q3 2018 | -7.2% | -9.0% | +25.3% | |
| Q2 2018 | +4.0% | +10.4% | +32.0% | |
| Q1 2018 | +9.1% | +14.2% | +25.9% | |
| Q4 2017 | +3.3% | +18.6% | -3.3% | |
| Q3 2017 | -3.1% | -8.5% | +6.2% | |
| Q2 2017 | +5.9% | +5.0% | +10.9% | |
| Q1 2017 | +1.1% | +0.0% | -2.2% | |
| Q4 2016 | +6.0% | +8.3% | +7.1% | |
| Q3 2016 | +2.2% | +10.8% | +8.6% | |
| Q2 2016 | +2.8% | +0.0% | -4.2% | |
| Q1 2016 | +2.5% | — | — | |
| Q4 2015 | -5.9% | — | — | |
| Q3 2015 | +2.9% | — | — | |
| Q2 2015 | -3.1% | — | — | |
| Q1 2015 | -7.4% | — | — | |
| Q4 2014 | +5.4% | — | — | |
| Q3 2014 | -8.1% | — | — | |
| Q2 2014 | +7.1% | — | — | |
| Q1 2014 | +1.3% | — | — | |
| Q4 2013 | +3.1% | — | — | |
| Q3 2013 | -16.6% | — | — | |
| Q2 2013 | -12.5% | — | — | |
| Q1 2013 | +0.5% | — | — | |
| Q4 2012 | -8.5% | — | — | |
| Q3 2012 | -17.4% | — | — | |
| Q2 2012 | -24.5% | — | — | |
| Q1 2012 | -2.4% | — | — | |
| Q4 2011 | -8.7% | — | — | |
| Q3 2011 | +0.4% | — | — | |
| Q2 2011 | -9.3% | — | — | |
| Q1 2011 | -5.6% | — | — | |
| Q4 2010 | -1.5% | — | — | |
| Q3 2010 | -8.1% | — | — | |
| Q2 2010 | -5.5% | — | — | |
| Q1 2010 | -0.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro